Royalty Pharma plc
$49.52
▲
0.08%
2026-04-22 10:12:13
www.royaltypharma.com
NMS: RPRX
Explore Royalty Pharma plc stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$28.52 B
Current Price
$49.52
52W High / Low
$50.08 / $31.58
Stock P/E
27.78
Book Value
$15.11
Dividend Yield
1.91%
ROCE
8.21%
ROE
13.2%
Face Value
—
EPS
$1.78
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
100
Beta
0.39
Debt / Equity
92.33
Current Ratio
2.4
Quick Ratio
2.4
Forward P/E
8.79
Price / Sales
11.65
Enterprise Value
$32.09 B
EV / EBITDA
20.53
EV / Revenue
13.49
Rating
Buy
Target Price
$51.56
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Protara Therapeutics, Inc. | $5.3 | — | $286.65 M | — | -32.51% | -31.6% | $7.82 / $2.77 | $3.67 |
| 2. | Benitec Biopharma Inc. | $13.99 | — | $483.71 M | — | -42.71% | -33.5% | $17.15 / $9.85 | $5.47 |
| 3. | Xeris Biopharma Holdings, Inc. | $6.25 | 1,885.02 | $1.04 B | — | 9.09% | -6.96% | $10.08 / $3.95 | $0.08 |
| 4. | Incyte Corporation | $97.69 | 15.26 | $19.46 B | — | 24.67% | 29.87% | $112.29 / $56.13 | $26.04 |
| 5. | eXoZymes, Inc. | $10.66 | — | $89.88 M | — | -220.6% | -1.33% | $18.4 / $7.08 | $0.4 |
| 6. | Bone Biologics Corporation | $1.38 | — | $2.5 M | — | -60.16% | -70.17% | $6.75 / $1.05 | $3 |
| 7. | MoonLake Immunotherapeutics | $17.89 | — | $1.32 B | — | -64.61% | -60.78% | $62.75 / $5.95 | $4.27 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 621.99 M | 609.29 M | 578.66 M | 568.25 M | 593.64 M | — |
| Operating Profit | 388.38 M | 427.16 M | 209.8 M | 534.18 M | 361.51 M | — |
| Net Profit | 214.21 M | 288.22 M | 30.18 M | 238.35 M | 208.21 M | — |
| EPS in Rs | 0.5 | 0.67 | 0.07 | 0.56 | 0.49 | 0.92 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.38 B | 2.26 B | 2.35 B | 2.24 B |
| Operating Profit | 1.56 B | 1.29 B | 1.49 B | 922.89 M |
| Net Profit | 770.95 M | 858.98 M | 1.13 B | 42.83 M |
| EPS in Rs | 1.8 | 2.01 | 2.65 | 0.1 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 19.62 B | 18.22 B | 16.38 B | 16.81 B |
| Total Liabilities | 9.91 B | 7.88 B | 6.3 B | 7.29 B |
| Equity | 6.48 B | 6.95 B | 6.53 B | 5.63 B |
| Current Assets | 1.53 B | 1.8 B | 1.27 B | 2.55 B |
| Current Liabilities | 636.21 M | 1.25 B | 161.38 M | 1.17 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 2.49 B | 2.77 B | 2.99 B | 2.14 B |
| Investing CF | -1.61 B | -2.68 B | -2.07 B | -1.03 B |
| Financing CF | -1.19 B | 361.14 M | -2.15 B | -944.86 M |
| Free CF | 2.49 B | 2.77 B | 2.99 B | 2.14 B |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -3.86% | 5.24% | — | — |
| Earnings Growth % | -24.31% | 2549.5% | — | — |
| Profit Margin % | 37.95% | 48.2% | 1.91% | — |
| Operating Margin % | 57.1% | 63.37% | 41.25% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | 68.76% | 80.15% | 18.94% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-02-20 | $0.235 |
| 2025-11-14 | $0.22 |
| 2025-08-15 | $0.22 |
| 2025-05-16 | $0.22 |
| 2025-02-21 | $0.22 |
Stock Splits
No stock split history available.